Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
Iversen OE, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, Block SL, Skrivanek A, Nur Azurah AG, Fong SM, Dvorak V, Kim KH, Cestero RM, Berkovitch M, Ceyhan M, Ellison MC, Ritter MA, Yuan SS, DiNubile MJ, Saah AJ, Luxembourg A. Iversen OE, et al. Among authors: dvorak v. JAMA. 2016 Dec 13;316(22):2411-2421. doi: 10.1001/jama.2016.17615. JAMA. 2016. PMID: 27893068 Clinical Trial.
Efficacy and safety of an adsorbent and anti-oxidative vaginal gel on CIN1 and 2, on high-risk HPV, and on p16/Ki-67: a randomized controlled trial.
Major AL, Dvořák V, Schwarzová J, Skřivánek A, Malík T, Pluta M, Mayboroda I, Grandjean EM. Major AL, et al. Among authors: dvorak v. Arch Gynecol Obstet. 2021 Feb;303(2):501-511. doi: 10.1007/s00404-020-05816-8. Epub 2020 Nov 20. Arch Gynecol Obstet. 2021. PMID: 33219482 Free PMC article. Clinical Trial.
An Adsorptive and Antioxidant Vaginal Gel Clears High-Risk HPV- and p16/Ki-67-Associated Abnormal Cytological Cervical Findings: A post-hoc Subgroup Analysis of a Prospective Randomized Controlled Trial on CIN2 and p16 Positive CIN1.
Major AL, Skřivánek A, Grandjean EM, Dvořák V, Malík T, Pluta M, Mayboroda I. Major AL, et al. Among authors: dvorak v. Front Med (Lausanne). 2021 May 25;8:645559. doi: 10.3389/fmed.2021.645559. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34113633 Free PMC article.
Correction to: Efficacy and safety of an adsorbent and anti-oxidative vaginal gel on CIN1 and 2, on high-risk HPV, and on p16/Ki-67: a randomized controlled trial.
Major AL, Dvořák V, Schwarzová J, Skřivánek A, Malík T, Pluta M, Mayboroda I, Grandjean EM. Major AL, et al. Among authors: dvorak v. Arch Gynecol Obstet. 2021 Feb;303(2):513-514. doi: 10.1007/s00404-020-05925-4. Arch Gynecol Obstet. 2021. PMID: 33415439 Free PMC article. No abstract available.
A phase II dose-ranging study of mirabegron in patients with overactive bladder.
Chapple CR, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele JJ, Bosman B, Boerrigter P, Drogendijk T, Ridder A, Van Der Putten-Slob I, Yamaguchi O; Dragon Investigator Group. Chapple CR, et al. Among authors: dvorak v. Int Urogynecol J. 2013 Sep;24(9):1447-58. doi: 10.1007/s00192-013-2042-x. Epub 2013 Mar 8. Int Urogynecol J. 2013. PMID: 23471546 Free PMC article. Clinical Trial.
262 results